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Background: To assess the within-trial cost-effectiveness of an NHS ovarian cancer screening (OCS) programme using data from
UKCTOCS and extrapolate results based on average life expectancy.
Methods: Within-trial economic evaluation of no screening (C) vs either (1) an annual OCS programme using transvaginal
ultrasound (USS) or (2) an annual ovarian cancer multimodal screening programme with serum CA125 interpreted using a risk
algorithm (ROCA) and transvaginal ultrasound as a second-line test (MMS), plus comparison of lifetime extrapolation of the no
screening arm and the MMS programme using both a predictive and a Markov model.
Results: Using a CA125–ROCA cost of d20, the within-trial results show USS to be strictly dominated by MMS, with the MMS vs C
comparison returning an incremental cost-effectiveness ratio (ICER) of d91 452 per life year gained (LYG). If the CA125–ROCA unit
cost is reduced to d15, the ICER becomes d77 818 per LYG. Predictive extrapolation over the expected lifetime of the UKCTOCS
women returns an ICER of d30 033 per LYG, while Markov modelling produces an ICER of d46 922 per QALY.
Conclusion: Analysis suggests that, after accounting for the lead time required to establish full mortality benefits, a national OCS
programme based on the MMS strategy quickly approaches the current NICE thresholds for cost-effectiveness when extrapolated
out to lifetime as compared with the within-trial ICER estimates. Whether MMS could be recommended on economic grounds
would depend on the confirmation and size of the mortality benefit at the end of an ongoing follow-up of the UKCTOCS cohort.
Ovarian cancer is the sixth most common cancer in women with
approximately 7300 new cases diagnosed in the United Kingdom
in 2013 (Cancer Research UK, 2016). Since the late 1970s,
incidence has increased by almost 15%. It remains the most
common cause of gynaecological cancer death. Whereas o5% of
women survive the disease for 5 years if diagnosed at the most
advanced stage (IV), when diagnosed early (at stage 1) 90%
survive.
A successful screening programme would therefore be a highly
valued public health-care intervention.
The primary aim of this paper is to draw on the clinical results
arising from the mortality reduction seen in the UK Collaborative
Trial of Ovarian Cancer Screening (UKCTOCS) to estimate a
within-trial period incremental cost-effectiveness ratio (ICER) to
assess the value to the UK National Health Service (NHS)-covered
population from the initiation of two screening scenarios as
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compared with a no-screening (control) group in which no
screening for ovarian cancer was undertaken (Jacobs et al, 2016).
The first screening programme was annual multimodal screening
(MMS), which is detection of raised serum levels of CA125 using a
risk of ovarian cancer algorithm (ROCA) to identify women who
may have ovarian cancer (potential cases). The second programme
relies on the identification of potential cases through annual
transvaginal ultrasound screening (USS). UKCTOCS reported
indicative findings that positive mortality benefit might well be
gained from an ovarian cancer screening programme. This paper
supplements the reported clinical results with estimates of the cost-
effectiveness of the MMS and USS screening programmes
compared separately with a no-screening arm based on individual
patient level trial data.
As well as presenting within-trial ICERs, we also present
incremental cost-effectiveness results for the MMS programme vs
no screening that extrapolates findings past the end of the
currently published 14-year follow-up in UKCTOCS. This
extrapolation helps to counter the long-lead times required to
establish the mortality benefits from an ovarian cancer screening
programme. Given the uncertainties involved in extrapolation, we
draw upon two different modelling approaches. The first is
founded upon direct predictions based on the underlying mortality
rates revealed by the trial and associated predicted costs. The
second uses a Markov model incorporating the UKCTOCS results
to extrapolate costs and effects over a hypothetical population
cohort. While necessarily adopting a different model structure, this
latter approach has the additional advantage of allowing assess-
ment of competing mortality risks and quality of adjusted life years
(QALY).
METHODS
Patients, setting and comparisons. In the UKCTOCS trial,
202 638 women aged between 50 and 75 years were recruited
between 17 April 2001 and 29 September 2005 through 13 UK
NHS Trusts. They were randomly allocated between 1 June 2001
and 21 October 2005 to either annual MMS (50 640) using serum
CA125 interpreted through an algorithm (ROCA) with transva-
ginal ultrasound as a second-line test or to annual transvaginal USS
(50 639 individuals) or to no screening (101 359 individuals)
(Jacobs et al, 2016). After exclusions relating to preexisting ovarian
cancer or death/loss to follow-up between randomisation and
initiation of screening, the total population of women analysed was
202 546, of which 101 299 were in the no-screening arm, 50 624
were in the MMS arm and 50 623 were in the USS arm. Screening
was completed at the end of 2011 with follow-up till the end of
2014.
The primary outcome was ovarian cancer death confirmed by
an independent outcome review committee by the end of
December 2014. Ovarian cancer was defined as malignant
neoplasms of the ovary (ICD-10 C56), which included primary
non-epithelial ovarian cancer, borderline epithelial ovarian cancer
and invasive epithelial ovarian cancer; malignant neoplasms of the
fallopian tube (ICD-10 C57.0); and undesignated malignancies of
the ovaries, fallopian tube or peritoneum. Primary peritoneal
cancer as defined by WHO 2003 was not part of the primary
outcome. The trial compared ovarian cancer deaths in the MMS
and USS vs no-screening groups. Survival time was estimated
from the date of randomisation to the date of death due to the
primary outcome or censoring (where censoring included death
from other causes or loss to follow-up). At the end of the study,
649 (0.32%) women had died of ovarian cancer: 347 (0.34%) in the
no-screening arm, 148 (0.29%) in the MMS arm; and 154 (0.30%)
in the USS arm. The mortality reduction over the complete follow-
up time of 14 years was 15% (95% CI  3 to 30; P¼ 0.10) in the
MMS arm and 11% (95% CI  7 to 27; P¼ 0.21) in the USS arm.
The cumulative hazards for the two screening arms began to
separate after 7 years for the MMS vs no-screening group and 9
years for the USS vs no-screening group comparisons, revealing a
substantial delayed effect of screening on mortality. Analysis of this
delayed effect showed that screening had a statistically significant
impact on mortality when this lead time was accounted for. Over
the later trial period, from 7 to 14 years, in the MMS screened
group there was a statistically significant mortality reduction of
23% (95% CI 1 to 46). For the USS group, the 7–14-year mortality
impact was 21% (95% CI  2 to 42). At censorship, the no-
screening group ovarian cancer mortality rate was continuing to
rise linearly, whereas the MMS and USS group rates appeared to be
plateauing (Jacobs et al, 2016).
Form of evaluation and perspective. In this analysis, we report an
incremental cost-effectiveness analysis of the MMS and USS
screening programmes separately comparing them to a no-
screening arm over the period of the trial. As USS is strictly
dominated (is more costly and less effective than) by MMS, the
USS vs control result is reported for information only for the
within-trial analysis. The analysis is based on individual patient-
level data collected during the trial and is assessed from the
perspective of a national NHS screening programme. We therefore
analyse only direct health service costs covering the programme
costs of the MMS and USS screening and the subsequent treatment
costs.
The primary cost-effectiveness analysis therefore relates to
assessment of the MMS and USS screening programmes compared
with the control population who were not subject to screening
within the trial follow-up period of 14 years. As there was a long-
lead time required to establish mortality benefit, as represented by
the separation of cumulative mortality rates and within trial hazard
rates only after 7 years across the screening arms and the control
arm of UKCTOCS (Jacobs et al, 2016; Figures 1, 2 and 3), and
given that USS was dominated by MMS, we also present a
secondary ICER for the MMS group alone compared with the no-
screening group estimated over a 25-year period through
extrapolating cumulative mortality and costs beyond the end of
the trial follow-up period of 14 years. The 25-year period was based
on the median age (60.6; IQR 56, 66) of women at randomisation
and UK ONS Life Table data estimating life expectancy at this age
to be approximately 25 years. Recognising the uncertainty
associated with extrapolation, we further undertake Markov
modelling of a hypothetical population cohort, based on the
UKCTOCS population, to extrapolate the ICER. The Markov
model is based on a (‘well’) population of 60-year-old females who
transition through states of benign oophorectomy, early-stage
ovarian cancer, advanced ovarian cancer, death from ovarian
cancer and death from competing mortality. Data taken directly
from UKCTOCS provided information on the states of benign
oophorectomy, early-stage ovarian cancer, advanced ovarian
cancer and death from ovarian cancer, while ONS Life Tables
provided the data on competing risks.
Health outcome. The effectiveness of the screening programme
was based directly on the trial primary outcome of mortality due to
ovarian cancer, which was converted to life years gained (LYG) for
the within-trial analysis. We used the Kaplan–Meier product limit
estimates of time to death from ovarian cancer, which were
reported in UKCTOCS (Jacobs et al, 2016), to calculate the average
gain in life expectancy for the MMS and USS screening arms
within the trial period as estimated by a calculated restricted mean.
The MMS extrapolation, estimated through predicted mortality
rates, also reports incremental cost per LYG from the screening
programme vs no screening, while the Markov model reports
QALYs through incorporating secondary data on QALY tariffs.
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Life years and QALYs gained were discounted at the UK National
Institute of Clinical Excellence (NICE) recommended rate of 1.5%
per annum for public health interventions as well as at the general
recommended rate of 3.5% per annum for health-care treatment
programmes (NICE, 2012a,b; NICE, 2013).
Resource use and cost. For each patient within the trial, all
resource usage relative to screening was captured. For those
referred for assessment due to screen findings, data related to
clinic visits, additional imaging, blood tests, trial related surgery,
all chemotherapy agents and the number of cycles recorded for
those treated for ovarian cancer and follow-up clinical assess-
ment was captured through review of medical notes. We
contacted treating clinicians irrespective of whether they were
located in the NHS or private sector to obtain medical notes. The
majority of the patients had treatment in the NHS with a small
minority treated privately. Only one woman who had undergone
trial surgery refused access to notes. Once we mapped resource
use, the 2013–2014 NHS tariff prices associated with relevant
hospital episodes (in-patient, day case and outpatient), proce-
dures, blood tests and clinics were attached to these visits
(Department of Health, 2014). The unit costs arising from
treatment of ovarian cancer with chemotherapy agents were
supplemented from a number of secondary sources, primarily
reports from NICE (UK) and the British National Formulary
prices (RICS, 2014).
The only exception to the use of published unit costs was the
unit cost of the CA125–ROCA test used to predict the likelihood of
ovarian cancer. This test is currently not available in the NHS. The
cost a private health care sector CA125 test is approximately d85
(range 75–95), relative to the NHS cost of the CA125 test of d10.
The cost of the ROCA as currently performed in the UK private
health-care sector is d150. The unit cost of the ROCA test in the
NHS was therefore estimated through using a UK private health
sector average 8.5-fold mark-up for CA125 over the NHS
diagnostic test costs, with a returned estimate of d17 for the
combined CA125–ROCA test if it were to be performed in the
NHS. An estimate of d20 was therefore used in the base-case
analysis and subjected to extensive sensitivity analysis to account
for the gross uncertainty surrounding this estimated NHS value.
The direct screening costs per patient over the trial period
represent approximately 50% of the total individual per patient
costs for those in the screening arms.
All unit costs are reported in Table 1. These unit costs, given in
2013/14 prices (d sterling), were combined with individual patient-
specific resource volumes to obtain a total cost per patient for each
type of resource and year. These were aggregated to provide a total
cost per patient over the entire period of the trial in each arm,
which was used to estimate the mean cost per patient screening
arm.
Given the presence of right censoring in the cost data, the
approach recommended by Lin et al (1997) was used to adjust the
within-trial cost estimates for censoring. As individual cost history
information at intermediate points in time was available, the
chosen estimator proposed by Lin et al (1997) partitions the entire
study period into discrete time intervals of 1 year in our case and
makes use of individual cost histories to derive an estimate of
average cost within each interval of the partition. The final estimate
of average cost over the whole period of analysis is then based on
weighting each interval cost estimate by the respective Kaplan–
Meier probability of survival to the start of the interval and
aggregating these interval cost estimates across the entire analysis
period. In this manner, an estimate of mean total cost per patient
adjusted for censoring was derived for each of the trial arms.
Combining the above cost and effect estimates to produce
differences in the average costs relative to differences in the average
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effects results in an ICER statistic for each comparison. To address
the uncertainty around these values, Fieller’s method for estimating
the confidence intervals of ratios was used (Fieller, 1954).
Extrapolation. Given the age of the trial population at randomi-
sation (median 60.6; IQR 56, 66) and that the evaluation assesses
the effects of a screening programme, extrapolating the within-trial
results out to 25 years was considered appropriate, as this is the life
expectancy of a 60-year-old female in the United Kingdom, in
order to capture the delayed effects of the programme while
accounting for its future costs.
Given the uncertainty associated with extrapolation, two
approaches were adopted. The first is based on predicting future
mortality and cost from the trial population data directly. The
second is based on Markov modelling of a hypothetical cohort that
used the within-trial data to estimate transition probabilities across
different states.
For the first extrapolation of effect, the parametric estimates of
time to ovarian cancer death by Royston and Parmar (2002),
which reported results consistent with the Kaplan–Meier
estimates over the trial period (Jacobs et al, 2016), were used to
predict LYG beyond the end of the trial. This allowed better
representation of the full gain in improved mortality from
ovarian cancer witnessed as screening was affected by consider-
able lead time. For the extrapolation the estimates by Royston and
Parmar were based on the specification shown to give the best fit
to the trial data through application of the Akaike Information
Criterion of model selection (Royston and Parmar, 2002). No
account was taken of competing risks given that there was no
(statistical) difference observed in these risks across the groups
within the trial. Analysis was therefore based purely on the trial-
estimated ovarian mortality rates. Extrapolated LYGs were
discounted at both 1.5% and 3.5%.
To estimate the relevant costs over the period of the
extrapolation, the method suggested by Etzioni et al (1999) was
adopted. Here the extrapolation period is disaggregated into years
and for each year the average cost was assumed to consist of two
components. The first component gives an estimate of average cost
for those who are expected to survive the year based on the within-
trial annual observed costs of the survivors and weighted by a
parametrically estimated probability of surviving the year. The
second component gives an estimate of average cost for those who
are expected to die in the year based on the within-trial annual
observed costs of those who die and weighted by the respective
estimate of the probability of dying in the year. To derive the
parametric estimates of survival for each year of the extrapolation
period, the estimates by Royston and Parmar were used.
Given the approach by Etzioni et al (1999) adopted here, as
detailed above, future costs are assumed to follow a similar pattern
to that observed within the trial, that is, they assume that patients
will continue to receive screening, testing and any necessary
treatment beyond the end of the trial and up to the end of the
extrapolation period.
The second method of extrapolation was based on a Markov
model, with a 1-year cycle, as given in Figure 1, which identifies the
transition and terminal states. All data, apart from that on
competing risk and quality of life (QoL), values were taken from
the UKCTOCS. The transitions from well-to-benign oophorect-
omy, early-stage ovarian cancer, late-stage ovarian cancer and
death from ovarian cancer were based on UKCTOCS within-trial
Kaplan–Meier estimates of annual hazards to these end points,
which were converted into annual transition probabilities. The
QoL data were taken from Edwards et al (2015) who reviewed 187
papers reporting QoL data relating to ovarian cancer, of which 27
provided data suitable for use in economic evaluations. Although
their concern was with advanced recurrent and refractory ovarian
cancer, the study reported QoL tariffs for stable and progressive
disease, estimated at 0.718 and 0.649, respectively. These values
were based on a sample population of 4600 patients and were
generally representative of values used for similar states in other
studies. We take these values to proxy the QoL tariffs for early-
stage ovarian cancer (0.718) and advanced ovarian cancer (0.649)
within the Markov model. The competing risk of mortality was
based on UK ONS Life Tables of annual mortality rates for 60-
year-old women, which when combined with the ovarian cancer
mortality rates allowed the cohort to be followed until all had
reached death.
For the Markov model, costs were attributed to each state on the
following basis. The screening cost was taken as CA125 plus ROCA
at d20, plus phlebotomy at d3 and a specialist gynaecological
outpatient visit cost of d109. The cost of benign oophorectomy was
d2,275 plus an additional outpatient follow-up visit of d139. Early
and advanced ovarian cancer was recorded for each of the
UKCTOCS participants. In the early ovarian cancer state that
includes borderline and non-epithelial ovarian cancer, based on the
trial findings an average of 49% of individuals received surgery
alone and 51% received surgery and chemotherapy, giving a
Table 1. Unit costs applied to the incremental cost-
effectiveness ratios
NHS hospital tariffs 2013–2014
Operation
In-
patient
Day
case
Outpatient
Laparotomy d2275 d569 d139
Operative laparoscopy d4852 d2075 d139
Hysteroscopy/D&C d1284 d898 d205
Diagnostic laparoscopy d2239 d1579 d205
Diagnostic laparoscopy/laparotomy d3523 d2477 d205
Vaginal surgery d1207 d484 d205
Hysterectgomy d3703 d1893 d156
Oophorectomy d2275 d569 d139
Omentectomy d2275 d569 d139
Excision
Colon d884 d590 d139
Bowel d5478 d565 d139
Appendectomy d3144 d1709 d139
Rectum d1461 d1040 d139
Spleen d3951 d1413 d139
Hormone replacement therapy (with
oophorectomy)
d2275 d569
Transvaginal ultrasound d150
Unit costs for tests and clinics 2013–2014
Cytology d8
Histopathology and histology d10
Intergrated blood services d2
Clinical biochemistry d1
Haematology d3
Immunology d5
Microbiology d7
Phlebotomy d3
Local gynaecological cancer MDT meetings d18
Specialist gynaecological cancer MDT meetings d109
Estimated CA125þROCA cost d20
Abbreviations: CA125¼ cancer antigen 125; D&C¼dilation and curettage; MDT¼
multidisciplinary team; NHS¼National Health Service; ROCA¼ risk of ovarian cancer
algorithm.
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weighted average cost of d3422, including all surgeries, che-
motherapies and outpatient follow-ups; while the advanced ovarian
cancer state, where 29% of UKCTOCS individuals had chemother-
apy, 8% had surgery alone and 63% had surgery and chemotherapy
had a weighted average cost, estimated on a similar basis of d5666.
Sensitivity analysis. Although the majority of costs reflect NHS
treatment costs, as noted above the combined CA125–ROCA unit
cost, which is central to the programme cost of the MMS arm, is at
present unknown within the NHS as the ROCA is not routinely
performed in the public sector. The d20 base-case CA125–ROCA
cost was estimated from the known UK private hospital sector cost
of the CA125 test and ROCA adjusted through the estimated
private-to-public hospital sector mark-up. Given the uncertainty
over this unit cost, univariate sensitivity analysis was undertaken
with the CA125–ROCA unit cost assessed at d15, d30, d40 and d50
per test, respectively, to assess the impact of this critical value on
the ICER estimates. This sensitivity analysis was applied to both
the within-trial and the predicted extrapolation analysis. The
Markov model applied probabilistic sensitivity analysis to a
distribution of CA125–ROCA costs ranging from d15 to d50
using a uniform distribution. Only the control vs MMS ICERs are
reported for the within-trial sensitivity analysis, the predicted
extrapolations and the Markov modelling as the trial USS strategy
is completely dominated by the MMS strategy.
Ethics. Ethical approval was by the UK North West Multicentre
Research Ethics Committees (North West MREC 00/8/34).
RESULTS
We report the ICERs for the within-trial comparisons of the MMS
group vs no-screening group and the USS group vs no-screening
group, as well as for the MMS vs control extrapolation beyond the
trial follow-up period of 14 years out to 25 years, the latter chosen
as reflecting a reasonable aggregate survival time when account is
taken of competing risks for the trial population. Results are
reported with discount rates at 1.5% applied to the effects (LYG
and QALYs) and to the costs, as the main results reflect the view
that screening is considered a public health intervention, and with
LYG and QALYs discounted at 3.5%. We report the within-trial
results as mean estimates accompanied by their variance
estimators, with ICERs reported together with their 95%
confidence intervals using the method by Fieller (1954).
The mean time to death, defined by the primary outcome
measure death from ovarian cancer, is reported in Table 2 by
screening arm. The results reproduce those reported in the
published UKCTOCS analysis and supplement these by the
discounted estimates of time to death from ovarian cancer using
discount rates of 1.5% and 3.5%. As can be seen, and consistent
with the trial results, the Kaplan–Meier estimated time to death
from ovarian cancer in the control arm is 13.5574 years
undiscounted and 12.36565 years when discounted at 1.5%
(11.01755 years when discounted at 3.5%). For the MMS treatment
arm, the respective times to death from ovarian cancer are 13.5607
years for undiscounted estimates and 12.3685 years when
discounted at 1.5% (11.01979 years discounted at 3.5%), while
for the USS arm they are 13.5597 years (undiscounted) and
12.3676 years when discounted at 1.5% (11.0191 years when
discounted at 3.5%).
Table 3 reports the mean cost per patient over the duration of
the study by programme allocation, discounted at 1.5% and 3.5%
per year, adjusted for censoring. As shown, and not surprisingly,
the no-screening arm exhibited extremely low costs over the trial
period; d135 discounted at 1.5% (d122 discounted at 3.5%) when
adjusted for censoring. These costs are essentially a ‘do-nothing’
intervention plus treatment costs arising from the small number,
relative to the total population, of individuals in this arm
presenting with ovarian cancer at some point within the trial.
The MMS group had a mean (adjusted for censoring) cost of d391
when discounted at 1.5%, (d360 discounted at 3.5%) during the
trial period. The USS screening arm had a much more expensive
mean (adjusted for censoring) cost of d1342 when discounted at
1.5% (d1259 discounted at 3.5%) during the trial period. In all
cases, these mean costs represent the screening cost plus any
treatment costs for detected ovarian cancer averaged or the
relevant population.
These cost and effect estimates formed the basis for the
estimation of the within-trial ICERs, which are reported in Table 4.
These ICERs are calculated as the incremental cost per LYG for the
MMS arm vs no-screening arm and the USS arm vs no-screening
arm. In each case, both costs and LYG are discounted at 1.5% as
well as 3.5%. The ICERs account for censoring in both cost and
effect estimates. As estimated, the USS vs no-screening ICER is
extremely high, calculated to be d625 801 (95% CI d620 451,
d631 245) per LYG at a 1.5% discount rate and d748 315 (95% CI
d741 446, d755 312) per LYG at a 3.5% discount rate. These high
values for the ICERs are due to a number of factors. First, the small
overall benefit derived in terms of time to death from ovarian
cancer from the within trial USS screening programme is a
reflection of the long-lead time, of around 7 years, to the associated
mortality gain from screening. Coupled with the effect of
discounting and the impact of the ICER being a calculated ratio,
this gives rise to the high USS ICER estimate.
The estimated within-trial cost per LYG arising from the MMS
programme is lower at d91 452 (95% CI d90 909, d92 001) per LYG
when discounted at 1.5% and d106 497 (95% CI d105 840,
d107 162) per LYG when discounted at 3.5% but remains relatively
high for similar reasons to those outlined for the USS vs
no-screening arm. Following these results and in accordance with
the approach adopted in the clinical trial mortality analysis (Jacobs
et al, 2016), the subsequent discussion of the cost-effectiveness of
the screening programme focuses on the comparison of the MMS
programme vs no-screening arms, given the dominance of MMS
over USS.
Given the long-lead time experienced to derive mortality benefit
and given that the UKCTOCs trial shows widely divergent hazard
rates across the control and MMS population after 7 years (Jacobs
et al, 2016), we extend the analysis to include an extrapolation of
the ICER out to 25 years. This extrapolated period of an additional
11 years is chosen as a reasonable length over which average life
expectancy in this age group, given competing risks, might be
extended; ONS estimates average life expectancy of a 60-year-old
female to be 25.22 years. Figure 2 shows the resultant extrapolated
cumulative survival curves for the MMS and no-screening arms,
which we believe to be conservative estimates of the health gain
from screening given the increasingly divergent hazard rates across
the MMS and no-screening groups seen in the trial analysis as
Table 2. Mean time to primary death by treatment group
within the trial period
Control
(N¼101299)
Multimodal
(N¼50624)
Ultrasound
(N¼50623)
Mean (s.e.)
Kaplan–Meier
(undiscounted)
13.55736 (0.0014) 13.56069 (0.0019) 13.55967 (0.0019)
Kaplan–Meier
(discounted at
1.5%)
12.36565 (0.0012) 12.36845 (0.0017) 12.36758 (0.0017)
Kaplan–Meier
(discounted at
3.5%)
11.01755 (0.0011) 11.01979 (0.0014) 11.01907 (0.0014)
Cost-effectiveness of UKCTOCS BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.222 623
documented in Figure 3 in Jacobs et al, 2016. The extrapolated
ICERs for the MMS vs no-screening population discounted at 1.5%
and 3.5% are also reported in Table 4 alongside the main within-
trial results. The reported ICERs reflect both increasing treatment
cost differences over time but, more importantly, increasing LYG
as the screening programme matures and are estimated at d30 033
per LYG when a discount rate of 1.5% is applied to both costs and
effects and at d35 544 per LYG when discounted at 3.5%.
The results of the univariate sensitivity analysis was limited to
the ICER for the MMS vs no screening and where the CA125–
ROCA unit cost were assumed to be d15, d30, d40 and d50 per
test, respectively, are reported in Table 5. These values were
deemed representative of the most plausible range of costs that
could be negotiated through the NHS for the CA125–ROCA test. A
value4d50 for this test was not considered, as the resultant ICER
estimate relating to the within-trial analysis reaches d173 258 per
LYG and even in the extrapolation period of analysis (for the MMS
vs no-screening comparison) the ICER is d56 962 per LYG. Further
increases in screening cost would merely push these ICERs higher.
In the within-trial sensitivity analysis, the estimated ICERs for
the MSS vs no-screening comparisons remain high. The average
cost per LYG ranges from d77 818 per LYG (Table 5; confidence
intervals also reported) when the CA125–ROCA cost was d15 to
d173 258 per LYG when the CA125–ROCA test costs was
increased to d50 and outcomes are discounted at 1.5% (if a
discount rate of 3.5% is applied, the ICER range is d90 549 per
LYG with the CA125–ROCA test cost d15 to d202 189 per LYG
with CA125–ROCA test cost d50).
Again, these relatively high within-trial ICERs reflect the fact
that there is a long-lead time associated with the accrual of the
mortality benefits gained from screening. Accounting for these
long-lead times through extrapolating the costs and mortality
benefits over a 25-year period, the ICERs fall considerably.
In the base-case predicted extrapolation analysis, using the
predictions of mortality rates by Royston and Parmar and the
method for extrapolating costs by Etzioni et al (1999), with the
CA125–ROCA test cost estimated at d20 and discounting at 1.5%,
the incremental cost per LYG for the MMS intervention was
calculated to be d30 033 per LYG compared with no screening
(d35 544 per LYG discounting at 3.5%). If the CA125–ROCA test
cost falls to d15, the ICER becomes d25 545 per LYG at a 1.5%
discount rate (d30 220 per LYG discounting at 3.5%). Over the
total 25-year period of analysis (within trial and extrapolation) at a
1.5% per annum discount rate, the ICER rises to d39 009 per LYG
with the CA125–ROCA test at d30, d47 986 per LYG with
the CA125–ROCA at d40 and d56 962 per LYG with the
CA125–ROCA test cost at d50.
For the Markov model, the extrapolated LYG are estimated to
be 0.039 when discounted at 1.5% and, although not directly
comparable as the model forces individuals through transition
states, are greater than the 0.014 LYG estimated through the
predictive extrapolation. Given that the Markov model incorpo-
rates competing mortality risk, the direction of difference is
correct. The extrapolated QALYs in the Markov model are
estimated to be 0.0581, as based on the average effect size seen
during the UKCTOCS holding across the extrapolation. The base-
case analysis in the Markov model comparing the MMS to no
screening estimates an ICER, using QALYs as the outcome, to be
d46 922 per QALY gained discounting at 1.5% (d54 267 per QALY
when both costs and effects are discounted at 3.5%). The
probabilistic sensitivity analysis, applying a uniform distribution
to a CA125–ROCA cost which lies between d10 and d50, returns a
minimum ICER of d45 030 per QALY and a maximum value of
d61 134 per QALY.
DISCUSSION
We report on the cost-effectiveness of screening using within-trial
data from one of the world’s largest multicentre randomised
controlled trials involving 202 546 women, 673 765(median of 8
per women in screen arms) annual screens and 2.2 million women-
years of follow-up. (Jacobs et al, 2016). Our analysis suggests that,
after accounting for the lead time required to establish full
mortality benefits, a national OCS programme based on the MMS
strategy when extrapolated out to lifetime could approach the
Table 3. Mean cost per patient over the trial period (ROCA¼ d20)
Control Multimodal Ultrasound
Meana Variancea Meana Variancea Meana Variancea
Adjusted for censoring, undiscounted d146 d40 d416 d56 d1412 d77
Adjusted for censoring, discounted at 1.5% d135 d30 d391 d47 d1342 d66
Adjusted for censoring, discounted at 3.5% d122 d22 d360 d38 d1259 d56
Abbreviation: ROCA¼ risk of ovarian cancer algorithm.
aMeans and variances were estimated using the estimator by Lin et al (1997).
Table 4. Incremental cost-effectiveness ratios for the MMS vs control and USS vs control comparisons within the trial period
(ROCA¼ d20)
Multimodal vs control Ultrasound vs control
Cost
difference
Effect
difference
ICER (95%
confidence interval)
Cost
difference
Effect
difference
ICER (95%
confidence interval)
Discounted at 1.5% and both costs and
effects adjusted for censoring
d256 0.0028 d91452 per LYG
(d90909, d92001)
d1208 0.00193 d625801 per LYG
(d620451, d631245)
Discounted at 3.5% and both costs and
effects adjusted for censoring
d239 0.00224 d106497 per LYG
(d105840, d107162)
d1137 0.00152 d748315 per LYG
(d741446, d755312)
Results for multimodal vs control ICER extrapolated to 25 years
Discounted at 1.5% d427 0.01421 d30033 per LYG
Discounted at 3.5% d358 0.01008 d35544 per LYG
Abbreviations: ICER¼ incremental cost-effectiveness ratio; LYG¼ life year gained; MMS¼multimodal screening; ROCA¼ risk of ovarian cancer algorithm; USS¼ ultrasound screening.
Note: ICER values differ from straight division of cost difference by effect difference due to rounding.
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current NICE thresholds for cost-effectiveness (d30 033 per LYG
on predictive extrapolation and d46 922 per QALY on Markov
modelling) as compared with the within-trial ICER estimates
(d91 452–d77 818 per LYG.). This suggests that MMS could be
recommended on economic grounds if a definitive mortality
benefit of 20% is confirmed on follow-up of the UKCTOCS cohort.
Data on cost-effectiveness of screening for ovarian cancer is
limited. The modelling undertaken is limited and based on various
assumptions concerning the reliability of screening regimes, with
few taking account of QoL considerations. Edwards et al (2015)
and Sfakianos and Havrileskey (2011) have provided comprehen-
sive reviews of this area, detailing that none have been based
on long-term trials. As a result, the evidence base for the
cost-effectiveness of screening for ovarian cancer is, to this
point, weak.
This analysis is the first to estimate ICERs based directly on
within-trial (UKCTOCS) individual patient data. Not surpris-
ingly, given the impact of the long-lead time taken to establish the
health benefits, the estimated within-trial ICERs are relatively
high. The most favourable within-trial ratio relating to the
comparison of the MMS arm vs no screening is calculated to be
d91 452 per LYG accounting for censoring in both cost and
mortality estimates and applying the NICE public health
programme discount rate of 1.5% per annum. It is important to
note that this relatively high cost-effectiveness ratio is not a result
of the average cost per patient being large over the trial period but
a direct consequence of the trial not being long enough to
adequately reflect the full mortality benefits likely to be gained
from the MMS programme.
As a result, the extrapolation of the within-trial results
becomes critical. Extrapolation highlights the problems of model
uncertainty, as well as the general issues surrounding prediction.
We have therefore resorted to two extrapolations: one based on
predictions of within-trial mortality rates and treatment costs
beyond the trial period and one based on the development of a
Markov model founded on data from the UKCTOCS trial applied
to a hypothetical cohort moved through a number of health
states.
Table 5. Incremental cost-effectiveness ratios for the MMS vs control and USS vs control comparisons within the trial period
(ROCA¼ d15)
Multimodal vs control Ultrasound vs control
Cost
difference
Effect
difference
ICER (95% confidence
interval)
Cost
difference
Effect
difference
ICER (95% confidence
interval)
Discounted at
1.5%
d218 0.0028 d77818 per LYG (d77356,
d78 285)
d1207 0.00193 d625300 per LYG (d619 954,
d630740)
Discounted at
3.5%
d203 0.00224 d90549 per LYG (d89990,
d91 115)
d1137 0.00152 d747717 per LYG (d740 854,
d754708)
Results for multimodal vs control ICER extrapolated to 25 years (ROCA¼d15)
Discounted at
1.5%
d363 0.01421 d25545 per LYG
Discounted at
3.5%
d305 0.01008 d30220 per LYG
(ROCA¼d30)
Discounted at
1.5%
d332 0.0028 d118721 per LYG (d118017,
d119 432)
d1210 0.00193 d626802 per LYG (621 443,
d632255)
Discounted at
3.5%
d310 0.00224 d138395 per LYG (d137542,
d139 258)
d1139 0.00152 d749510 per LYG (d742 630,
d756518)
Results for multimodal vs control ICER extrapolated to 25 years (ROCA¼d30)
Discounted at
1.5%
d554 0.01421 d39009 per LYG
Discounted at
3.5%
d466 0.01008 d46194 per LYG
(ROCA¼d40)
Discounted at
1.5%
d409 0.0028 d145989 per LYG (d145125,
d146 864)
d1212 0.00193 d627804 per LYG (d622 436,
d633265)
Discounted at
3.5%
d381 0.00224 d170292 per LYG (d169243,
d171 354)
d1141 0.00152 d750705 per LYG (d743 814,
d757724)
Results for multimodal vs control ICER extrapolated to 25 years (ROCA¼d40)
Discounted at
1.5%
d682 0.01421 d47986 per LYG
Discounted at
3.5%
d573 0.01008 d56843 per LYG
(ROCA¼d50)
Discounted at
1.5%
d485 0.0028 d173258 per LYG (d172233,
d174 296)
d1214 0.00193 d628805 per LYG (d623 428,
d634275)
Discounted at
3.5%
d453 0.00224 d202189 per LYG (d200945,
d203 449)
d1143 0.00152 d751900 per LYG (d744 998,
d758930)
Results for multimodal vs control ICER extrapolated to 25 years (ROCA¼d50)
Discounted at
1.5%
d809 0.01421 d56962 per LYG
Discounted at
3.5%
d680 0.01008 d67492 per LYG
Abbreviations: ICER¼ incremental cost-effectiveness ratio; LYG¼ life year gained; MMS¼multimodal screening; ROCA¼ risk of ovarian cancer algorithm; USS¼ ultrasound screening.
Note: ICER values differ from straight division of cost difference by effect difference due to rounding.
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One advantage of the Markov modelling is that it can
incorporate QoL data gained from outside the trial. Although
extensive QoL data were collected during the trial, these were
related to screening or profile data and are not readily convertible
to the tariff values required to calculate QALY gains (Barrett et al,
2014). The calculation of QALYs would have, for example, allowed
precise quantitative estimation of the impact that screening
complications and false-positive results had on the QoL of the
women involved. Such an impact, we believe would have been
small as o1% of the women in either the USS or MMS screening
arms experienced screen complications, all of which were mild
such as bruising or discomfort during scanning/blood test, while
the number of false-positive surgeries performed were 50 per
10 000 screens in the USS group and 14 per 10 000 screens in the
MMS group. The costs of these false-positive surgeries are captured
in all the reported analysis, but it is only in the Markov analysis
that QALY estimates were provided.
The predictive modelling of the ICER provides an estimate for
the MMS programme relative to the no-screening population
extrapolated out to a 25-year period that falls dramatically to
d30 033 per LYG when a discount rate of 1.5% is applied (d35 544
per LYG when a discount rate of 3.5% is applied), while for the
Markov model the extrapolated cost per QALY, in an analysis that
also incorporates competing mortality risks, is estimated to be
d46 922 per QALY.
Both provide indicative evidence that, if using the conventional
NICE threshold of d20 000 per QALY to d30 000 per QALY to deem
interventions cost-effective, a screening strategy based on the MMS
programme fast approaches becoming cost-effective when compared
with the within-trial analysis when the programme is lengthened
using within-trial mortality benefits as the basis of extrapolation.
The long-lead time associated with establishing mortality benefit
from ovarian cancer screening has meant that the full benefits to be
realised from such a programme have not been established
authoritatively. This is further complicated by the presence of
preexisting cancers within the trial population at the first screen.
Indeed, in a prespecified secondary analysis that excluded
prevalent cases from the analysis population a statistically
significant 28% mortality reduction was shown in the MMS arm
after 7 years of the trial (Jacobs et al, 2016). If this increased
mortality gain were to convert into a larger gain in time to survival
for the MMS arm, this would greatly improve the cost-effectiveness
estimates given that we are using extremely low values in the
denominator of the calculated ICERs. Given that the trial
population is a mixed cohort of prevalence and incidence cases,
more complex modelling than undertaken here would be required
to fully establish this case.
The findings are not only highly dependent on the average effect
size of the mortality reduction associated with screening but also
the cost of the CA125–ROCA test, assuming this test is adopted by
the NHS. The base-case analysis of the predictive extrapolation
model and of the Markov model both use a CA125–ROCA cost of
d20. Even this seems relatively high as the current average NHS
cost for histopathology and histology tests within the NHS are d10.
Moreover, if as is possible given the continuing divergence of the
hazard rates for the no-screening and MMS arms at censorship for
mortality analysis, the screening effect benefit continues to grow,
the ICER will continue to approach the NICE threshold. We have
been deliberately conservative, given the uncertainties associated
with extrapolation and prediction and the difficulties of estimating
the cost to the NHS of the CA125–ROCA test.
In conclusion, the results of the extrapolation over lifetime
suggest that a public health programme of screening for ovarian
cancer could become cost-effective within an NHS setting if the
mortality benefit from screening continues to increase over time.
Any definitive conclusion as to whether MMS could be
recommended on economic grounds would depend on the
confirmation and size of the mortality benefit at the end of
ongoing follow-up of the UKCTOCS cohort.
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